Quest Diagnostics Incorporated · NYSE:DGX

Quest Diagnostics — Q4 2024 Earnings Presentation

7 slides from Quest Diagnostics's earnings presentation, Jan 30, 2025

  1. Slide 1: Guidance for Full Year 2025

    Guidance for Full Year 2025 January 30, 2025

  2. Slide 2: Safe Harbor Disclosure

    The statements in this presentation which are not historical facts may be forward- looking statements. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date that they are made and which reflect management’s current estimates, projections, ex

  3. Slide 3: Note on Non-GAAP Financial Measures

    As used in this presentation the term “reported” refers to measures under accounting principles generally accepted in the United States (“GAAP”). The term “adjusted” refers to non-GAAP operating performance measures that exclude Note on Non- special items such as restructuring and integration charge

  4. Slide 4: Guidance for full year 2025

    Low High Net revenues $10.70 billion $10.85 billion Guidance for Net revenues increase 8.4% 9.9% full year 2025 Reported diluted EPS $8.34 $8.59 Adjusted diluted EPS $9.55 $9.80 Cash provided by operations Approximately $1.45 billion Capital expenditures Approximately $500 million 4  CONFIDENTIAL

  5. Slide 5: 2025 Adjusted Diluted EPS Guidance Bridge

    2025 Adjusted Diluted EPS Guidance Bridge ~$0.04 $0.00-$0.05 $0.65-$0.75 ~($0.20) $0.78-$0.88 ~($0.50) $9.55-$9.80 ~($0.05) ~($0.10) $8.93 2024 Organic Acquired CrowdStrike Haystack MRD Investments** Interest Tax Rate Share Count 2025 Adjusted Revenue Revenue Expense Dilution Adjusted Diluted EPS Gr

  6. Slide 6: Underlying assumptions for full year 2025 guidance

    • Revenue guidance assumes approximately 3% organic revenue growth with the remainder coming from the acquisitions closed in 2024. It does not assume any contribution from prospective M&A that could be completed in Underlying 2025. assumptions • The company absorbed a headwind in 2024 related to the

  7. Slide 7: Non-GAAP Reconciliations

    • The following table reconciles adjusted results to reported results under accounting principles generally accepted in the United States. Year ended Year ended December 31, December 31, 2025 2024 Low High Reported diluted EPS $7.69 $8.34 $8.59 Amortization of intangible assets (a) 0.84 1.05 1.05 Re

Quest Diagnostics — Q4 2024 Earnings Presentation on 6ix